Modular Medical, Inc. has received FDA clearance for its Pivot insulin pump, a next-generation tubeless patch pump designed for ease of use and affordability. The company aims to expand the insulin pump market beyond 'super users' to the mass market, targeting both Type 1 and Type 2 diabetes patients. Commercial availability and initial shipments of the Pivot pump commenced in June 2026, with plans for expansion into metropolitan markets by late 2026. The company also plans to obtain CE mark clearance for the Pivot product by the second quarter of 2027 to enter European markets. Modular Medical reported net losses of $28.2 million for the year ended March 31, 2026, and $18.8 million for the year ended March 31, 2025, highlighting the need for continued capital raising. The company has a history of operating losses and expects to continue incurring losses as it scales operations and commercialization efforts.